JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - Piper Sandler has reduced its price target on Oscar Health Inc (NYSE:OSCR) to $13.00 from $14.00 while maintaining a Neutral rating on the health insurance company. The stock, currently trading at $14.93 with a market capitalization of $3.88 billion, has shown impressive revenue growth of 48% over the last twelve months, according to InvestingPro data.
The adjustment follows Oscar Health’s mixed second-quarter 2025 results reported last week, along with the company’s affirmation of its revised full-year 2025 guidance that was initially announced on July 22, 2025.
Oscar Health has articulated expectations for a return to profitability in calendar year 2026, though Piper Sandler noted "significant questions" remain regarding both the revised 2025 guidance and the company’s path to profitability next year.
The research firm’s new price target is based on an unchanged multiple applied to a lower calendar year 2027 estimated adjusted earnings per share of $0.92, down from the previous estimate of $1.06.
Piper Sandler indicated it hopes to engage with Oscar Health’s management in the coming weeks to gain better understanding of the assumptions underlying both the 2025 guidance and 2026 profitability projections.
In other recent news, Oscar Health reported its second-quarter earnings, which did not meet analyst expectations. The company announced an earnings per share (EPS) of -$0.89, falling short of the anticipated -$0.84. Additionally, Oscar Health’s revenue was reported at $2.86 billion, which was below the forecasted $2.92 billion. These figures indicate that both earnings and revenue missed projections. The company’s financial performance was closely watched by investors and analysts alike. Despite the earnings miss, the company continues to be a subject of interest in the investment community. Analyst opinions and future expectations may vary, but the current data highlights the challenges Oscar Health is facing in meeting market forecasts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.